| abstract |
Humanized monoclonal antibodies, mouse monoclonal antibodies or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to glycosylated and deglycosylated human CD47 with an optimized Koff value, disrupt the interaction of human CD47 with SIRP, and find use in a variety of therapeutic, prophylactic, or diagnostic methods. The present invention includes isolated antibodies and their derivatives and fragments, pharmaceutical compositions containing one or more humanized or chimeric monoclonal antibodies against CD47, and cell lines that produce these monoclonal antibodies. Also provided are the amino acid and nucleotide sequences of these antibodies. |